Pembrolizumab combo before/after surgery and radiation significantly improved event-free survival in resectable advanced head ...

The combination of the PARP inhibitor olaparib and the PD-1 inhibitor pembrolizumab showed initial antitumor activity with no new safety signals in a molecularly matched, tumor-agnostic trial, ...

The addition of neoadjuvant and adjuvant pembrolizumab to standard of care significantly improved outcomes for certain ...

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during ...

Summit Therapeutics highlights China approval of Akeso's ivonescimab for NSCLC, with enrollment ongoing for Phase 3 HARMONi-7 ...

Adding perioperative pembrolizumab to standard care can improve EFS in locally advanced head and neck cancer, data suggest.

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or ...

Ravindra Uppaluri, MD, PhD, lead investigator of the phase 3 KEYNOTE-689 trial (NCT03765918), highlights the potential of pembrolizumab (Keytruda; Merck) to improve outcomes following head and neck ...

Ten (10) patients have achieved an objective response (5 confirmed) when treated with MDNA11 alone or in combination with KEYTRUDA® (pembrolizumab) – all responders had advanced and/or metastatic canc ...

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during and after standard-of-care surgery had longer event-free survival without ...

An immunotherapy treatment could ‘change the world’ for newly diagnosed head and neck cancer patients, giving them an extra two-and-a-half years of life.